ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Staff Advisory Boards To Be Formed; Three BSCs Proposed

August 11, 1995

Gleevec Decreases Recurrence Of Gastrointestinal Tumor

April 27, 2007

In Brief: Whittaker Corp, Trying To Hire NCI Director; Environmental Carcinogenesis On NCAB Agenda

February 13, 1976

Blood Donors With Undertrain HTLV-3 Should Be Notified, Consensus Panel Says

July 18, 1986

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

NCI R01 Payline Stays At 12th Percentile for FY07.

February 9, 2007